As biologics, biomarker-enriched trials and real-world evidence reshape the COPD landscape, sponsors face both new opportunities and increasing complexity. Success depends on translating these advances into effective cli...
Biotech
Developing transformative therapies with small & mid-sized biopharma companies requires a flexible approach
PlayFrom here to where?
Plotting a course to bring APAC-developed drugs to the world
Download Global and China biotech survey reports
Two new survey reports of 260+ Global and China-based biotech leaders are ready to download.
Driving biotech success at every milestone
Biotech companies are pioneering the future of medicine from genomic breakthroughs to first-in-class immunotherapies. With focused pipelines and bold ambitions, many biotechs operate without the full infrastructure of larger organizations, making speed, precision, and strategic support essential.
ICON delivers the expertise, technology, and global reach to turn biotech innovation into impact. Our empowered structure enables fast decision-making and flexible engagement, backed by the scale of one of the world’s most innovative CROs.
Our dedicated biotech teams are built to understand your unique pressures and priorities, collaborating closely, sharing ownership, and delivering results at every stage of development.
Our four-pillar approach, Patients, People, Process, and Partnership, is designed to transform biotech ambition into real-world impact. By combining patient-centric strategies, expert talent, streamlined operations, and collaborative engagement, ICON empowers you to deliver life-changing therapies faster.
Emerging biotech funding
As new funding models and investor priorities reshape the biotech landscape, companies must navigate a dynamic environment with agility and foresight to secure the capital needed for innovation.
Behind Biotech
Our experts bring more than scientific knowledge - they bring purpose, perspective, and a commitment to partnership.
Partnering with biotechs to transform ideas into life-changing therapies.
ICON provides end-to-end capabilities, from early-phase design to market access; ensuring agility, scalability, and scientific excellence throughout the development journey.
-
Тailored clinical development
8,000 professionals dedicated to biotech delivering agile, customized solutions built around your needs.
-
Consulting and advisory services
Strategic guidance from early development through to commercialization.
-
Therapeutic expertise
Deep experience across therapeutic areas, from first-in-human to late-phase trials.
-
Tools and technologies
Innovative platforms that accelerate research and enhance data-driven decisions.
Emerging biotech, empowered for investment
ICON partners with biotech innovators to sharpen funding strategies, align with investor expectations, and drive value across every stage of development.
Optimising biotech funding whitepaper series
In this two-part whitepaper series on biotech funding, we firstly share insights on how biotechs can secure funding in a highly competitive market, and then shed light on the opportunities available to utilise these funds more effectively and efficiently.
Early phase challenges for biotechs
This whitepaper explores the growing challenges facing biotech during early phase drug development, and how these can be navigated to ensure the best possible outcomes.
Case studies
Explore our biotech case study library showcasing real-world success stories where bold ambition meets ICON’s expertise.
Empowering biotech innovation at every stage of development.
Through advanced analytics, global trial expertise, and strategic partnerships, ICON enables biotechs to streamline processes and achieve faster, smarter outcomes.
Early, precise and efficient
The methods and technologies advancing Alzheimer’s and Parkinson’s R&D
In this CNS whitepaper, which includes extracts from our survey of over 120 neurodegenerative therapeutic developers, we examine how innovative methodologies and technologies are being implemented to improve the success rate of clinical trials across a range of neurodegenerative disorders.
Procedural and regulatory know-how for China biotech in the EU
How to navigate EU MAA regulations and registration
Learn how to navigate the European Medicines Agency registration and regulation procedures and gain access to a potential patient pool of 500 million people.
2023 biotech sector survey
The biotech industry stands at a pivotal moment, navigating funding challenges with resilience and adaptability. After a period of remarkable growth and investment, the landscape shifted abruptly in 2022, and 2023 continued to present its own set of challenges.
De-risking clinical development of precision medicines in oncology
This whitepaper reviews the most pressing challenges and opportunities facing the oncology therapeutic landscape in the emerging era of precision medicine, and reports on how those opportunities and challenges vary by organisational size and region.
Digital disruption
The clinical research industry is making strides in technological innovation, with small but steady increases to the percentage of companies implementing and piloting digital technologies. However, our 2024 digital disruption survey conducted with Citeline shows a slower pace of innovation than predicted by the 2019 survey. Why is this the case?
Obesity and beyond
Embracing multi-indication potential during clinical development
This whitepaper explores the strategic rise of multi-indication drug development for obesity and its comorbidities, offering insights into clinical trial design, regulatory pathways, and commercial opportunities based on recent industry trends and survey data.
.jpeg?crop=yes&w=1017&h=1017&a=325,0&itok=ZQ_TVcyw "obesity_scan_icons"){kind=icon}
Building strong foundations: regulatory insights for biotechs.
Through early engagement strategies, deep procedural expertise, and global regulatory insight, ICON equips biotechs to anticipate challenges, streamline submissions, and accelerate access to key markets worldwide.
Early engagement and regulatory considerations for biotech
Gain insight into the common questions small and emerging biotech companies face, and the importance of early engagement and regulatory affairs when developing an asset and considering a drug development partner.
Biotech blogs and media contributions
-
Media article: A new chapter for biotech: Confidence returns to the market
In this article from Fierce Biotech, Chris Smyth, President of ICON Biotech outlines reasons for optimism in 2024, as the biotech sector looks to bounce back after several challenging years.
-
Media article: Revolutionising Drug Development: Key Takeaways from the ICON Biotech Survey
In this article from The Journal of mHealth, Chris Smyth, President of ICON Biotech, dissects the challenges and opportunities discovered in ICON's recent biotech sector survey.
-
Blog: Strategies for de-risking rare disease programmes during research and development
ICON experts share how biotechs can maximise funding for rare disease therapeutic development in our blog.
-
Media article: ICON biotech sector survey: Insights and projections shaping the industry
In this article from PM360, Chris Smyth, President of ICON Biotech, summarises the main findings from the biotech sector survey and outlines the key implications for biotech including strategic collaboration, innovation and cost optimisation.
-
Media article: Capitalising on collaboration and confidence: Survey insights and expectations for biotech in 2024
This article by Chris Smyth, President, ICON Biotech, provides an overview of the recent ICON biotech sector survey findings, and looks at the trend of biotech companies engaging earlier and more comprehensively with CROs to drive efficiencies and realise the full value of their R&D programs.
-
Media article: Optimism returns as biotech optimise R&D
In this article, Brandon Early, SVP Project Delivery, outlines some of the key findings from the ICON biotech sector survey of over 130 decision makers in small, mid-size, large biotech and VC organisations.
-
Media article: ICON predicts biotech trial demand will grow despite economic pressures
This article from Clinical Insider outlines ICON’s view that the demand for clinical trial services will increase in 2024, in addition to providing an overview of the results of the recent ICON biotech sector survey, the findings of which suggest that biotech R&D spending is likely to increase.
-
Media article: 48% of biotechs leaning on Big Pharma as current funding method: ICON survey
This article from Fierce Biotech provides an overview of findings from the ICON 2023 biotech sector survey.
Start the conversation
Start the conversation with our biotech team to explore how ICON can accelerate your clinical development and deliver investor-ready trial strategies tailored to your goals.
